<DOC>
	<DOCNO>NCT00931840</DOCNO>
	<brief_summary>This Phase 2 , multicenter , multiple-arm , open-label study evaluate efficacy , safety , tolerability EZN-2208 . EZN-2208 administer single agent patient K-RAS mutation tumor . Patients wild type K-RAS tumor randomize EZN-2208 + cetuximab standard care ( Camptosar® + cetuximab ) , patient must fail regimen contain irinotecan ( Camptosar® , CPT-11 ) , oxaliplatin ( Eloxatin® ) , fluoropyrimidine . After discontinuation study treatment , patient receive care consider appropriate investigator . Patients continue follow disease progression , subsequent anticancer therapy , survival .</brief_summary>
	<brief_title>A Study EZN-2208 Administered With Without Cetuximab Patients With Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description>EZN-2208 administer i.v . infusion weekly 3 week 4-week cycle . The cetuximab infusion administer EZN-2208 ( Arm B ) irinotecan ( Arm C ) infusion . Study treatment continue evidence disease progression , unacceptable toxicity , withdrawal patient 's consent participation study . Approximately 220 patient enrol study : approximately 100 patient K-RAS mutate arm approximately 120 patient wild-type K-RAS arm .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients must meet follow criterion eligible enrollment study . 1 . Histologically confirm CRC adenocarcinoma metastatic locally recurrent CRC nonresectable 2 . Patients must agree genetic test original metastatic CRC tumor biopsy tissue KRAS mutational status . 3 . Disease progression 4 . Previous therapy irinotecan , oxaliplatin , fluoropyrimidine either alone combination ( ) . Patients must radiographically document progressive disease receiving , within 3 month receive , agent alone combination . 5 . No 2 prior cytotoxic chemotherapy regimen . 6 . Age 18 year old 7 . Measurable disease RECIST Version 1.1 8 . ECOG performance status 0 1 9 . Adequate bone marrow , renal , hepatic function Patients meet follow exclusion criterion eligible enrollment . 1 . Known chronic infectious disease 2 . Major surgery within 3 week study start 3 . Known suspected brain metastasis require intervention steroid and/or radiation therapy . 4 . Prior chemotherapy , immunotherapy , noninvestigational agent , therapy use treat cancer within 3 week schedule administration EZN2208 5 . History primary cancer within 5 year enrollment , unless 1 . Curatively resect nonmelanomatous skin cancer , 2 . Curatively resected cervical cancer 6 . Lack recovery Grade 1 reversible side effect relate administration investigational agent , prior treatment cancer 7 . Any condition uncontrollable diabetes , uncontrollable hypertension , active infection . 8 . Current participation another clinical study investigational agent and/or use investigational drug ( include investigational use approve drug ) 30 day first administration EZN2208</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>EZN-2208 ( PEG-SN38 )</keyword>
</DOC>